Results 101 to 110 of about 11,797,694 (349)

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

open access: yesMolecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser   +14 more
wiley   +1 more source

Formulation and Evaluation of Gastroretentive Dosage Form of Ofloxacin

open access: bronze, 1970
Prabhakar Reddy Veerareddy   +6 more
openalex   +2 more sources

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

open access: yesMolecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu   +18 more
wiley   +1 more source

Spectrofluorometric Determination of Pindolol and Its Dosage Form [PDF]

open access: bronze, 1983
Mohamed E. Mohamed   +2 more
openalex   +1 more source

Understanding and measuring mechanical signals in the tumor stroma

open access: yesFEBS Open Bio, EarlyView.
This review discusses cancer‐associated fibroblast subtypes and their functions, particularly in relation to extracellular matrix production, as well as the development of 3D models to study tumor stroma mechanics in vitro. Several quantitative techniques to measure tissue mechanical properties are also described, to emphasize the diagnostic and ...
Fàtima de la Jara Ortiz   +3 more
wiley   +1 more source

Development of a Dosage form for a Photoswitchable Local Anesthetic Ethercaine. [PDF]

open access: yesPharmaceuticals (Basel), 2023
Noev A   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy